Clinical Trial of ARQ 761 in Advanced Solid Tumors

Phase 1 Completed 91 enrolled University of Texas Southwestern Medical Center ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Primary Objective: To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761 administered intravenously. Secondary Objectives: To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor activity of aRQ 761

Timeline

Start: 2011-12-29
Primary completion: 2017-02
Completion: 2019-03

Publications

Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA. Phase 1 study of ARQ 761, a beta-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARQ761	Small molecule	195 mg/m2	Intravenous
Subject	ARQ761	Small molecule	390 mg/m2	Intravenous
Subject	ARQ761	Small molecule	450 mg/m2	Intravenous
Subject	ARQ761	Small molecule	550 mg/m2	Intravenous
Subject	ARQ761	Small molecule	660 mg/m2	Intravenous
Subject	ARQ761	Small molecule	800 mg/m2	Intravenous
Subject	ARQ761	Small molecule	1000 mg/m2	Intravenous

Clinical Trial of ARQ 761 in Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications